Background: Overdiagnosis is the main harm of cancer screening programs but is difficult to quantify. This review aims to evaluate existing approaches to estimate the magnitude of overdiagnosis in cancer screening in order to gain insight into the strengths and limitations of these approaches and to provide researchers with guidance to obtain reliable estimates of overdiagnosis in cancer screening. Methods: A systematic review was done of primary research studies in PubMed that were published before January 1, 2016, and quantified overdiagnosis in breast cancer screening. The studies meeting inclusion criteria were then categorized by their methods to adjust for lead time and to obtain an unscreened reference population. For each approach, we provide an overview of the data required, assumptions made, limitations, and strengths. Results: A total of 442 studies were identified in the initial search. Forty studies met the inclusion criteria for the qualitative review. We grouped the approaches to adjust for lead time in two main categories: the lead time approach and the excess incidence approach. The lead time approach was further subdivided into the mean lead time approach, lead time distribution approach, and natural history modeling. The excess incidence approach was subdivided into the cumulative incidence approach and early vs late-stage cancer approach. The approaches used to obtain an unscreened reference population were grouped into the following categories: control group of a randomized controlled trial, nonattenders, control region, extrapolation of a prescreening trend, uninvited groups, adjustment for the effect of screening, and natural history modeling. Conclusions: Each approach to adjust for lead time and obtain an unscreened reference population has its own strengths and limitations, which should be taken into consideration when estimating overdiagnosis.
ecological and cohort studies do not represent a single approach, but multiple approaches that may affect the reliability of overdiagnosis estimates in different ways. Therefore, the current review aims to evaluate existing approaches to estimate overdiagnosis in cancer screening, using breast cancer screening as example, in order to gain insight in the strengths and limitations of each approach and provide researchers with guidance to obtain reliable estimates of overdiagnosis in cancer screening.
Methods

Literature Search and Study Selection
We executed a systematic review to identify studies on overdiagnosis in cancer screening. Although overdiagnosis has been quantified for various cancer screening programs, previous research has shown that most studies quantifying overdiagnosis in cancer screening focused on breast cancer screening. In addition, the studies available for breast cancer screening cover all considered approaches to estimate overdiagnosis, with the exception of autopsy studies and pathological and imaging studies (1) . We chose to exclude pathological and imaging studies from the current review because these have been reviewed and discussed previously by Carter et al. (1) and cannot be evaluated in the same manner as ecological, cohort, and modeling studies. As a consequence, we could limit our review to studies estimating overdiagnosis in breast cancer screening, resulting in a more focused result section, without missing important approaches.
We used the query "(breast neoplasms )" to search for relevant articles in Pubmed that were published before January 1, 2016. We only included primary studies in English that estimated overdiagnosis in breast cancer screening. Because adjustment for lead time and comparison with an unscreened reference population are essential for the estimation of overdiagnosis, we did not include studies missing at least one of these items (8) .
Data Extraction
From each study, one person extracted the study population, type of data, method to adjust for lead time, method to obtain the unscreened reference population, the reported methodological limitations, and strengths and the outcome (measure, type of data, and percentage of overdiagnosis) (see Supplementary Table 1 , available online). The extracted data were checked by two other persons, and uncertainties were discussed with all authors.
Results
Four hundred and forty-two records were identified and screened for relevance ( Figure 1 ). Forty studies met inclusion criteria and were included in the qualitative synthesis. The studies included in this review were categorized according to the approach to adjust for lead time and the approach to obtain an unscreened reference population (see Table 1 ).
Approaches to Adjust for Lead Time
Most cancer screening programs aim to detect cancers in a preclinical stage with better treatment options in order to prevent cancer death. A certain proportion of the cancer precursors and cancers detected in the preclinical phase would have become symptomatic if screening had not occurred. For these nonoverdiagnosed cancers, only the time of diagnosis is advanced; this time period between the detection by screening and when the cancer would have been clinically diagnosed is known as the lead time (see Figure 2 , scenario 1). However, screening also detects cancers in a preclinical phase that would never have become symptomatic during an individual's lifetime, that is, overdiagnosed cancers ( Figure 2 , scenario 2). When estimating the number of cancers that are overdiagnosed by screening, it is necessary to distinguish between cancers that are detected early and would have become symptomatic if screening had not occurred and cancers that are overdiagnosed. In other words, it is necessary to correct for the lead time of cancers that would have been clinically detected without screening. There are several methods to adjust for lead time; they are usually divided into two groups: the lead time approach and the excess-incidence approach (2, 6) .
Lead Time Approach
The lead time approach is based on a direct adjustment for lead time. Basically, overdiagnosis is estimated by comparing the cancer incidence in an unscreened population with the cancer incidence in a screened population adjusted for lead time. There are, however, several different approaches to adjust for lead time; they range from simple to more sophisticated: the average lead time approach, the lead time distribution approach, and natural history modeling (see Table 2 ). The first two approaches, the average lead time and lead time distribution approach, both require an estimate of the mean lead time in order to adjust the cancer incidence in a screened population for lead time. The natural history and lead time of an individual cancer is unfortunately unobservable. There are, however, several approaches to estimate the mean lead time. For breast cancer, the most common method to estimate the mean lead time is the method of Day and Walter (9-13). The average lead time approach, also called the incidence rate approach (5) or rate shift approach (10) , uses the estimated mean lead time to shift the cancer incidence rate: The cancer incidence in the unscreened reference population is compared with the cancer incidence in the screened population a number of years earlier (ie, the length of the mean lead time). Because the number of latent cases is the highest at the first screening examination, the first screening examination is often excluded from analyses to allow the estimation of overdiagnosis in a steady state of screening. Most authors do not, however, exclude all first screens, but estimate overdiagnosis from a steady state period where the number of persons having their first screen is small. Until now, this approach has been applied six times to estimate overdiagnosis in breast cancer screening (14) (15) (16) (17) (18) (19) . The main limitation of this approach is that it requires the exclusion of the first screening round (ie, prevalent round), resulting in an underestimation of overdiagnosis.
The second approach, the lead time distribution approach, assumes that the length of the lead time varies and follows an exponential distribution. With this distribution, it is possible to estimate the probability that a currently asymptomatic screendetected cancer becomes symptomatic, and thus detectable without screening, after a specific time point. The number of screen-detected cancers that would have become symptomatic can then be added to the cancer incidence in the unscreened reference population (10) or subtracted from the number of screen-detected cancers (11, 12) . Either way, the cancer incidence will be adjusted for lead time and the cancer incidence in the screened and unscreened populations can be compared to estimate overdiagnosis. So far, this approach has been applied three times to estimate overdiagnosis in breast cancer screening (10) (11) (12) . The major limitation of this approach is that the natural history and lead time of cancers cannot be observed, requiring assumptions to estimate lead time and, thus, overdiagnosis.
The last approach to directly adjust for lead time is natural history modeling. Generally, natural history models consider the entire disease process: the moment when carcinogenesis leads to the development of preclinical disease, the progression of preclinical disease, and the detection of the disease because of symptoms; in addition, these models incorporate information on the performance of screening tests to model the detection of preclinical disease by screening. This approach has been applied 10 times to estimate overdiagnosis in breast cancer screening (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . Each type of model requires slightly different input data and assumptions, the details of which go beyond the scope of the current evaluation. Generally, natural history models require background information on cancer incidence and mortality, clinical data (eg, age and stage by mode of detection, including data from a nonscreened population), screening data (ie, detection rates by age, stage, and round, interval cancers), and information on background mortality for causes other than the investigated cancer. In case of (micro)simulation models, this data is used to simulate the reality: Under certain assumptions, the model should give the same outcomes (eg, cancer incidence and mortality) as observed, in settings with screening and without screening. If this is the case, the model is "well-calibrated" or "well-fitted." Overall, the main limitation of models is that different combinations of assumptions can give the same model fit because of the statistical dependency between the parameters for the sensitivity of the screening test and the preclinical duration, which causes uncertainty in the model estimates (30) .
In general, the lead time approach is a useful method to estimate overdiagnosis directly because it does not require a long period of follow-up after screening cessation. But at the same time, it also requires a number of assumptions on the natural history of cancer to estimate lead time and overdiagnosis. Therefore, inadequate estimates of lead time will result in biased estimates for overdiagnosis (31) .
Excess Incidence Approach
The excess incidence approach adjusts for the consequences of early detection by screening (ie, lead time) on cancer incidence. Figure 2 . Explanation of lead time. As shown in Figure 3 , cancers that are detected early and would have become symptomatic if screening had not occurred (ie, nonoverdiagnosed cancers) will cause an increase in the cancer incidence during screening and a drop in the incidence after screening cessation compared with a no-screening situation, until the end of the lead time. However, overdiagnosed cancers cause an increased incidence during screening that is not compensated for by a drop after screening cessation. In a screening setting, the extra cancer incidence during screening is thus caused by a combination of nonoverdiagnosed and overdiagnosed cancers, which will lead to an incomplete compensatory drop after screening cessation. Currently, there are two approaches to distinguish the extra incidence from nonoverdiagnosed cancers and overdiagnosed cancers: the cumulative incidence approach and the early-vs late-stage cancer approach. The first approach, that is, the cumulative incidence approach, is the most common approach and has been applied in 21 studies to estimate overdiagnosis in breast cancer screening (8, 17, 20, (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) . This approach uses the effect displayed in Figure 3 to estimate overdiagnosis: It estimates the cumulative incidence in a screened population (both during screening and after cessation of screening) and compares this with the cumulative incidence in an unscreened population. The difference in incidence between the two populations then represents the number of overdiagnosed cases, under the condition that the analysis is carried out appropriately. There are, however, three important conditions that need to be fulfilled for adequate estimation: 1) screened individuals need to cease screening, 2) the follow-up after cessation of screening needs to be as long as the longest lead time, and 3) the cancer incidence during screening and after screening cessation needs to be estimated from the same individuals or individuals with a similar cancer risk and screening participation rates (52, 53) . The second condition simply requires a long follow-up period; conditions 1 and 3 can both be fulfilled by estimating overdiagnosis in birth cohorts rather than in time periods. The main limitation of the cumulative incidence approach is directly related to the conditions needed for adequate estimation: It requires a long period of follow-up, and it needs to estimate overdiagnosis in birth cohorts when cancer risk and participation rates vary.
REVIEW
The second excess incidence approach is the early-vs latestage approach. This approach has only been used once to estimate overdiagnosis in breast cancer screening (54, 55) and has received much criticism (56) (57) (58) . The basic idea of this approach is that early detection by screening will increase the incidence of early-stage cancers, which comprise both overdiagnosed cancers and nonoverdiagnosed cancers. The increase in early-stage cancers that is not compensated by a decrease in symptomatic cancers (ie, reflected by late-stage cancers) represents the number of overdiagnosed cancers. To arrive at a reliable estimate for overdiagnosis, a number of conditions need to be fulfilled, the most important being 1) an unambiguous cutoff point to group cancers either as preclinical (ie, early stage) and symptomatic (ie, late stage) and 2) an adjustment for the shift in age and calendar period caused by early detection (ie, adjustment for lead time). The last condition can be fulfilled by estimating the increase in early-stage cancer and decrease in late-stage cancer in a birth cohort that stops screening and is followed until there is no decrease in late-stage cancers anymore. As for the cumulative incidence approach, the main limitations of the early-vs late-stage approach are also directly related to the conditions needed for adequate estimation, namely the absence of an unambiguous cutoff point to distinguish early-and late-stage cancers and the need for a long follow-up period after screening cessation.
Generally, the excess incidence approach is theoretically a robust method that does not require assumptions on lead time. Figure 3 . Effect of nonoverdiagnosed and overdiagnosed cancers on the cancer incidence. 
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However, it requires the follow-up after cessation of screening to be as long as the longest lead time, which is seldom reached in studies that have used this approach.
Approaches to Obtain an Unscreened Reference Population
Overdiagnosed cancers are cancers that would not have been detected in the absence of screening. Thus, to estimate the number of overdiagnosed cancers, the cancer incidence in a screened population should ideally be compared with the cancer incidence in a comparable unscreened population with follow-up until death (59) . Until now, seven methods have been used to estimate the breast cancer incidence in an unscreened population: a control group of a randomized controlled trial (RCT), nonattenders, control region, extrapolation of a prescreening trend, uninvited groups, adjustment for the effect of screening, and natural history modeling. Table 3 presents the seven methods to estimate cancer incidence in the absence of screening and gives an overview of the required data, assumptions, and the major strengths and limitations. Please note that all methods described in Table 2 also require information on cancer incidence in the absence of screening.
Randomized Controlled Trial
In an RCT, participants are randomly assigned to a screened intervention group and an unscreened control group. This is the best approach to obtain a screened and an unscreened population with similar underlying cancer risks. In the last decades, eight RCTs have been executed to estimate the (additional [41] ) effect of mammographic screening on breast cancer mortality (40, 42) . These RCTs provide individual-level data that can be used to estimate overdiagnosis using the cumulative-incidence approach (41,49) or a lead time approach (34, 49) . If perfectly executed, RCTs control for different types of bias including selfselection bias and contamination. However, most RCTs are not perfect: Some individuals in the intervention group will not adhere to the intervention, and some individuals in the control group will have opportunistic screening. This contamination causes a dilution in the overdiagnosis estimate. These limitations are not restricted to mammography screening (60) . Furthermore, most RCTs that have been executed cannot be used to estimate overdiagnosis because they have severe limitations with respect to the conditions required to adequately estimate overdiagnosis, such as inadequate randomization (42), screening of the control group at the end of the trial (40), physical examination in the control group (41), and/or long-term follow-up in which a national screening program was implemented (41, 49, 61 (32, 33, 35, 39, 45) . The exact methodology to estimate overdiagnosis differs slightly between these studies, but the underlying idea is the same. The individuals selected for the study, from a database (33), cohort (35, 39, 45) , or case-control study (32) , are divided into two groups: ever attended vs never attended. The ever-and never-attending groups can be further subdivided into screening phases, including prevalent screening, subsequent screening, and a period after leaving the screening program (35) . For each group, incidence rates are calculated, and the incidence rate ratio can be used to compare the breast cancer incidence in attenders and nonattenders. The evaluated studies differ mainly in the way they estimate overdiagnosis: One study used the difference in standardized incidence rates (33) , two studies used the incidence rate ratio (39, 45) , and two studies used the absolute difference in the cancer incidence (32, 35) . The main strength of the nonattenders approach is the use of individual data, which allows one to estimate overdiagnosis in persons actually screened rather than persons who have the opportunity to be screened. This prevents dilution of the overdiagnosis estimates and provides estimates that are more informative to persons planning to participate in screening. There are, however, a number of limitations associated with the nonattenders approach, including self-selection bias, small nonadjustable lead time bias, misclassification of exposure and difficulty in estimating the number of overdiagnosed cases. First, the choices of individuals to become attenders or nonattenders may be correlated with differences in the baseline risk of cancer, so-called self-selection bias. Self-selection bias may cause an overestimation or underestimation of overdiagnosis, depending on the direction of the self-selection (62, 63) . Second, comparison of incidence rates of attenders and nonattenders will introduce a small lead time bias because screening advances the time of diagnosis (ie, lead time) and attenders with a screen-detected cancer will therefore on average contribute fewer person-years (ie, smaller denominator) than nonattenders with cancer. Third, the exposure for irregular attenders may be misclassified because the attenders and nonattenders are simply classified as either ever attended or never attended. This may result in an underestimation of overdiagnosis (ie, dilution of the effect). Finally, the calculation of overdiagnosis is not straightforward for this approach because the cancer incidence in nonattenders cannot be adjusted for risk factors or needs another reference population, for example, estimated through extrapolation of prescreening trends (32, 35) , to estimate overdiagnosis.
Control Region
A geographically distinct region with no (organized) cancer screening program or cancer screening recommendations can also serve as an unscreened reference population. Until now, this approach has been used six times to estimate overdiagnosis in breast cancer screening in the Netherlands (44), Sweden (15), Norway (17) , and Denmark (19, 38, 43) . Two studies used individual data (19, 43) , and four studies used data at the population level (15, 17, 38, 44) .
Compared with other ecological approaches to obtain an unscreened reference population (ie, uninvited groups and extrapolation of prescreening trends), the strength of a control region is that it does not require assumptions with regards to incidence over time or age groups. However, it does require the assumption that the screened and unscreened regions are comparable with respect to the underlying risk of cancer, cancer detection (when screening does not occur), and registration of cancer diagnoses. Most studies using this approach to estimate overdiagnosis in breast cancer screening acknowledge that the screened region and unscreened control region may differ in their risk of breast cancer, and therefore they adjusted for differences in breast cancer incidence trends between both regions (15, 17, 38, 43) . Overdiagnosis can, however, still be affected by other differences between both regions, such as opportunistic screening (38) . Another limitation of this approach is that it can no longer be executed for breast cancer in most countries because most countries implemented a population-based screening program (Europe and Australia) or provided the entire population with screening recommendations (United States).
Extrapolation of a Prescreening Trend
The cancer incidence in absence of screening can also be obtained by extrapolating the observed prescreening cancer incidence trend to the screened period. This approach has been used 11 times and is thereby the most common approach used to estimate overdiagnosis in breast cancer screening using observational data (10) (11) (12) 14, 16, 33, 34, 37, 40, 46, 50, 54) . The basic idea of this approach is simple: select a period before the introduction of screening and estimate the trend in cancer incidence using either linear regression on rates or Poisson regression on counts. Then, the trend in cancer incidence is extrapolated to the current screening era to obtain the cancer incidence in an unscreened reference population.
The major strength of this approach is its simplicity and the fact that it can be executed in most countries. Extrapolation of prescreening trends requires, however, at least two assumptions that are not always fulfilled. First, extrapolation requires that the cancer incidence trend would remain the same if screening had not been introduced. Second, it assumes that case ascertainment and other factors related to cancer diagnosis remain the same, which is unlikely knowing that diagnostic procedures and systems have evolved over the last decades. An extra assumption is required when the prescreening trend is adjusted for a trend in a nonscreened age group, namely that the change in the cancer incidence in the screened and nonscreened age groups is similar. Apart from the fact that the assumptions made to extrapolate prescreening trends are not likely to be fulfilled, it has been shown that there is strong statistical uncertainty surrounding the prescreening trend. Overdiagnosis estimates depend heavily on the assumptions made to extrapolate the trend, especially on the choice of the prescreening period (40, 64) .
Uninvited Groups
Groups that are not invited to cancer screening, that is, uninvited birth cohorts or uninvited age ranges, may also serve as unscreened reference populations. To obtain the unscreened reference population, this approach does not just use the observed values in the uninvited group, but adjusts the cancer incidence in the uninvited age group for differences between the invited and uninvited groups. Until now, this approach has been used twice to obtain an estimate of overdiagnosis in breast cancer screening (14, 36) . One study used the cancer incidence in uninvited age ranges (40 years and 80 years) to estimate the incidence in the screened age range by assuming a linear increase in incidence with age (14) . The other study used the cancer incidence in an uninvited birth cohort (1930) (1931) (1932) (1933) (1934) and adjusted the cancer incidence for birth cohort effects through statistical modeling to obtain a comparable unscreened reference population (36) .
In comparison with the other ecological approaches, the strength of using uninvited groups to obtain an unscreened population is that it does not require assumptions on trends over time or on equality between two regions with respect to factors influencing the cancer incidence. However, this approach does require a different set of assumptions. For example, interpolation of cancer incidence from uninvited age groups assumes a linear increase in incidence with age, which is not likely to hold for breast cancer (eg, Clemmenson's hook in the perimenopausal age range). Furthermore, this approach assumes no opportunistic screening in the uninvited age groups. Although this "no (opportunistic) screening" assumption applies to more approaches, it is more likely to fail for uninvited age groups or birth cohorts that are directly followed by screened age groups or birth cohorts because these groups may unintentionally be invited for screening and/or are more likely to have an opportunistic screening exam.
Adjust for the Effect of Screening
An unscreened reference population can also be obtained by adjusting the cancer incidence in a screened population for the effect of screening. The incidence in the unscreened population is thus not observed, as was the case with the previous approaches, but it is estimated from a statistical model. Currently, this approach has been used four times to estimate overdiagnosis by mammographic screening (18, 36, 47, 48) . The approach uses a Poisson regression model or negative binomial regression model to estimate the cancer incidence based on factors like age, period, cohort, and screening uptake. Then, the effect of screening on cancer incidence is removed in order to obtain the cancer incidence in an unscreened population. The existing models differ slightly in the factors used to explain the cancer incidence: Some incorporate several risk factors (18, 48) , and some stratify the effect of screening by type of screening examination (eg, first and subsequent) (47, 48) .
Compared with previously described methods, the main strength of using statistical adjustment for the effect of screening to obtain the unscreened population is that it does not require assumptions about the equality of the screened and unscreened populations. Because the screened and unscreened populations are obtained from the same statistical model that only differs in the effect of screening, both populations are equal. Besides, this approach may be favored over more complex natural history models because it is rather simple and requires fewer assumptions. However, the simplicity of the statistical model may also be its pitfall: It may sometimes be too simplistic. The statistical model does, for example, indirectly assume that the effect of (the different phases of) screening on cancer incidence is constant, which does not reflect changes in screening practice. Furthermore, estimating cancer incidence using a limited number of parameters may not result in an adequate model fit, although this is seldom reported (47) .
Natural History Modeling
The last approach to obtain an unscreened reference population is natural history modeling. As natural history models incorporate the entire disease process (the moment when carcinogenesis leads to the development of preclinical disease, the progression of preclinical disease, and the detection of the disease due to symptoms) and the effect of screening, they can provide estimates for the occurrence of a disease for screened and unscreened populations with the exact same characteristics. The main limitations of modeling are related to its underlying assumptions, which are more closely related to lead time than the unscreened reference population, and therefore already discussed under the lead time approach.
Discussion
This qualitative synthesis classified the epidemiological methods used to estimate overdiagnosis in (breast) cancer screening according to two important characteristics: adjustment for lead time and the specification of the unscreened reference population. There were two main approaches to adjust for lead time and seven different approaches to obtain an unscreened reference population. For each approach, we gave an overview of the required data, the assumptions needed, and the major strengths and limitations.
The two main methods to adjust for lead time were the lead time approach and the excess incidence approach. Although this grouping of methods to adjust for lead time is well known (6), there is much debate about the best method to adjust for lead time (3, 65, 66) . Some authors explicitly prefer the excess incidence approach over the lead time approach because the latter relies on lead time assumptions that may be false (65) . However, the excess incidence approach has drawbacks as well, which are mainly related to the data and the prerequisites for adequate estimation of overdiagnosis. Therefore, one approach cannot simply be preferred over the other. In contrast, using both approaches and recognizing their limitations may help to achieve consensus on accurately estimating overdiagnosis (2) .
In this review, we also subdivided the main methods to adjust for lead time. The lead time approach was subdivided into three groups, which ranged from simple to complex: mean lead time, lead time distribution, and natural history modeling. Overall, there is a direct relationship between the complexity of the method and the number of assumptions required: The more complex the approach, the higher the number of assumptions. When using the lead time approach, it is therefore important to make a balanced decision on the number of assumptions and the reliability of the estimate. For example, the simplest method (ie, mean lead time) requires only a few assumptions but will underestimate overdiagnosis-when the perfect lead time is available and used-because it excludes the "prevalent round." On the other hand, natural history modeling can estimate overdiagnosis for all screening rounds or exams but requires more assumptions. The excess incidence approach was further subdivided into two groups: the cumulative incidence approach and early-vs late-stage approach. We showed that both approaches need to fulfill different conditions for adequate estimation of overdiagnosis; these conditions are rarely fulfilled in existing studies.
Although most (review) studies so far focused on the adjustment for lead time, this review also included the choice of the unscreened reference population as one of the major characteristics influencing overdiagnosis estimates. We showed that there are seven different approaches to obtaining an unscreened reference population: a control group of an RCT, nonattenders, control region, extrapolation of a prescreening trend, uninvited groups, adjustment for the effect of screening, and natural history modeling.
All approaches to obtain an unscreened reference population have limitations and strengths, which we discussed in this review. Nevertheless, some approaches can be favored over others. To this end, researchers can use general guidelines, such as the well-known hierarchy of study designs (from high to low: RCTs, cohort studies, case-control studies, and ecological studies) and guidelines on the type of data (individual data is favored over population-level data [4] ), to choose the most adequate approach. Nevertheless, judgment of the reliability of overdiagnosis estimates based on these guidelines alone is not appropriate. This requires a careful examination of all the strengths and limitations of both the approach used to obtain the unscreened reference population and the approach to adjust for lead time. A high-evidence design with a poor adjustment for lead time can thus give poorer estimates than an evidence design of poorer quality and better adjustment for lead time.
This review did not focus on the actual overdiagnosis estimates in the selected studies, but rather on the evaluations of the strengths and limitations of the methods used to quantify overdiagnosis in breast cancer screening. As a consequence, we did not provide an estimate or range of estimates for overdiagnosis by mammographic screening. Other reviews have judged overdiagnosis estimates and provided a range of the most reliable overdiagnosis estimates, which differs between the reviews (1,5,7). However, our review indicates that it is not straightforward to give a range of reliable estimates of overdiagnosis because many studies suffer from severe limitations and overdiagnosis is often not defined in a uniform way (see Supplementary Table 1, available online) .
Furthermore, we focused on studies quantifying overdiagnosis in breast cancer screening to evaluate the limitations and strengths of lead time adjustment and the choice of unscreened reference population. There are also studies quantifying overdiagnosis in screening for prostate cancer, lung cancer, and colon cancer (1) . However, these studies provide no additional approaches beyond the ones presented in the current article. We would, however, like to point out that not all approaches presented in this review are suitable to estimate overdiagnosis (67) in all cancer screening programs. For example, overdiagnosis in cancer screening programs that focus on detecting cancer precursors (eg, cervix and colon cancer) and screening for cancers with no trial or implemented screening program can only be estimated using natural history modeling. Moreover, we would like to point out that the impact of each limitation on overdiagnosis estimates may differ between cancer screening programs. For example, a short follow-up period after screening cessation leads to a greater overestimation of overdiagnosis for cancers with a long lead time, for example, prostate cancer (68), than for cancers with a shorter lead time, for example, lung cancer (67) .
The overarching goal of this qualitative review on the approaches to estimate overdiagnosis is to make a contribution to the search for the best method to derive the "true" overdiagnosis estimate for each cancer screening program. To this end, we would like to make some recommendations for future research. First, we encourage researchers to apply multiple methods to estimate overdiagnosis. In the application of each method, researchers should aim to fulfill the assumptions-as described in this review-and, if not possible, hypothesize what the effect of the unfulfilled assumptions on the estimated percentage of overdiagnosis will be. Second, we think it is worthwhile to investigate the effect of each assumption of each approach on the overdiagnosis estimate. For example, previous research-using prescreening trends to obtain an unscreened reference population-showed that the choice of the prescreening period affects the overdiagnosis estimate (64) . This gives some indication of how sensitive overdiagnosis estimates are to the chosen assumptions in various approaches. Third, researchers are encouraged to reach consensus regarding the definition of overdiagnosis and to apply the same denominator to estimate the percentage of overdiagnosis. We have previously provided a suggestion for the definition of overdiagnosis, which includes screen-detected and interval cancers in the denominator, expresses the percentage of overdiagnosis as a real percentage, and is unaffected by attendance percentages and applicable to all observational study designs (69) . This denominator can help to obtain overdiagnosis estimates that are comparable across different approaches. If these recommendations are adopted, multiple and comparable overdiagnosis estimates will become available, which will make it possible to obtain an indication of the "true" overdiagnosis estimate for specific cancer screening programs.
To conclude, overdiagnosis can be estimated using different approaches. There are two main methods to adjust for lead time and seven different approaches to obtain an unscreened reference population. Each approach has its own strengths and limitations, which should be taken into consideration when estimating overdiagnosis.
